These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2566199)

  • 61. [Effect of neuroleptic treatment on positive and negative symptoms of schizophrenia and the results of the dexamethasone test].
    Rybakowski J; Linka M
    Psychiatr Pol; 1991; 25(1):1-6. PubMed ID: 1685787
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Changes of plasma concentrations of interleukin-1 alpha and interleukin-6 with neuroleptic treatment for schizophrenia.
    Xu HM; Wei J; Hemmings GP
    Br J Psychiatry; 1994 Feb; 164(2):251-3. PubMed ID: 7909714
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Acute colitis associated with prolonged administration of neuroleptics.
    Larrey D; Lainey E; Blanc P; Diaz D; David R; Biaggi A; Barnéon G; Bottai T; Potet F; Michel H
    J Clin Gastroenterol; 1992 Jan; 14(1):64-7. PubMed ID: 1348258
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies.
    Goldberg TE; Weinberger DR
    J Clin Psychiatry; 1996; 57 Suppl 9():62-5. PubMed ID: 8823353
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The therapeutic latency of neuroleptic drugs and nonspecific postjunctional supersensitivity.
    Freed WJ
    Schizophr Bull; 1988; 14(2):269-77. PubMed ID: 2904695
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Schizophrenic deficit syndrome and neurologic tolerance].
    Verdoux H; Bourgeois M
    Encephale; 1996 Jun; 22 Spec No 2():45-7. PubMed ID: 8767042
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Neuroleptic depression in schizophrenia.
    Harrow M; Fichtner CG; Grossman LS; Yonan CA; Sands J
    Biol Psychiatry; 1991 Oct; 30(8):845-8. PubMed ID: 1684298
    [No Abstract]   [Full Text] [Related]  

  • 68. Prediction of treatment response in schizophrenia: clinical use of neuroleptic blood levels.
    Tang SW
    Can J Psychiatry; 1985 Jun; 30(4):249-50. PubMed ID: 2861888
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Neuroleptic effects on interhemispheric and intrahemispheric performance of tactile discrimination tasks by schizophrenic patients.
    Tomer R
    Psychiatry Res; 1990 Jun; 32(3):289-96. PubMed ID: 1975103
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Disturbed circadian rest-activity cycles in schizophrenia patients: an effect of drugs?
    Wirz-Justice A; Haug HJ; Cajochen C
    Schizophr Bull; 2001; 27(3):497-502. PubMed ID: 11596850
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Addition of lithium to neuroleptic treatment in chronic schizophrenia.
    Lewis HA; Bacher NM; Field PB
    Am J Psychiatry; 1986 Feb; 143(2):262. PubMed ID: 2868667
    [No Abstract]   [Full Text] [Related]  

  • 72. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity.
    Hogan TP; Awad AG; Eastwood R
    Psychol Med; 1983 Feb; 13(1):177-83. PubMed ID: 6133297
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cellular immunity in schizophrenic patients before and during neuroleptic treatment.
    Müller N; Ackenheil M; Hofschuster E; Mempel W; Eckstein R
    Psychiatry Res; 1991 May; 37(2):147-60. PubMed ID: 1678892
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Drug therapy in schizophrenia--variability of outcome and prediction of response.
    Awad AG
    Can J Psychiatry; 1989 Oct; 34(7):711-20. PubMed ID: 2572318
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The effects of antipsychotic medication on sequential inhibitory processes.
    Salo R; Robertson LC; Nordahl TE; Kraft LW
    J Abnorm Psychol; 1997 Nov; 106(4):639-43. PubMed ID: 9358694
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Gender and the use of neuroleptics in schizophrenia. Further testing of the oestrogen hypothesis.
    Salokangas RK
    Schizophr Res; 1995 Jul; 16(1):7-16. PubMed ID: 7547647
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cytokine production in unmedicated and treated schizophrenic patients.
    Rothermundt M; Arolt V; Leadbeater J; Peters M; Rudolf S; Kirchner H
    Neuroreport; 2000 Oct; 11(15):3385-8. PubMed ID: 11059907
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The reliability of 5-hydroxytryptamine induced platelet aggregation responses in schizophrenic patients treated with neuroleptic drugs.
    Knox JM; Orr MW; Allen R; Gelder MG; Grahame-Smith DG
    Br J Clin Pharmacol; 1981 Mar; 11(3):261-3. PubMed ID: 6111334
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Treatment with neuroleptics: the patient's perspective.
    Windgassen K
    Acta Psychiatr Scand; 1992 Nov; 86(5):405-10. PubMed ID: 1362474
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Neuroleptic medication and reduced risk of prostate cancer in schizophrenic patients.
    Mortensen PB
    Acta Psychiatr Scand; 1992 May; 85(5):390-3. PubMed ID: 1351334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.